Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations

被引:18
|
作者
Shubrook, Jay H. [1 ]
Neumiller, Joshua J. [2 ]
Wright, Eugene [3 ]
机构
[1] Touro Univ Calif, Coll Osteopath Med, Vallejo, CA USA
[2] Washington State Univ, Coll Pharm & Pharmaceut Sci, Spokane, WA USA
[3] Charlotte Area Hlth Educ Ctr, Performance Improvement, Charlotte, NC USA
关键词
Diabetic kidney disease; type; 2; diabetes; chronic kidney disease; urinary albumin to creatinine ratio; ANGIOTENSIN-ALDOSTERONE SYSTEM; GLOMERULAR-FILTRATION-RATE; SGLT2; INHIBITORS; CARDIOVASCULAR OUTCOMES; RECEPTOR AGONISTS; GLYCEMIC CONTROL; FINERENONE; ALBUMINURIA; NEPHROPATHY; BLOCKADE;
D O I
10.1080/00325481.2021.2009726
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at high risk of CKD progression and cardiovascular (CV) disease. Prevalence of CKD in patients with T2D is currently around 40% and continues to grow. The increasing number of people with CKD and T2D will ultimately have a significant impact upon health resource use and costs of care for people with T2D. Management of CKD in patients with T2D aims to preserve kidney function to reduce the risk of end-stage kidney disease, CV events, and mortality. Evidence-based recommendations for the treatment of patients with CKD and T2D are provided by several international and national organizations and recommend several lifestyle and pharmacological approaches to help prevent or delay the progression of CKD in patients with T2D. Guidelines include regular screening of patients with T2D for CKD using spot urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (at least annually and at least twice a year if UACR >300 mg/g). Additionally, assessment of vascular complications, together with interventions designed to improve glycemic control and lipid levels, maintain healthy body weight, and optimize blood pressure should be performed. Medications shown to slow progression of CKD include renin-angiotensin system inhibitors, sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists, and, more recently, selective, non-steroidal mineralocorticoid receptor antagonists. This review highlights the ongoing challenges facing primary care providers in the management of CKD in patients with T2D including the consideration of comorbidities, adoption of new treatment options, and implementation of individualized care. Achieving consensus for optimal treatment of this disease is critical in providing consistent and appropriate care for all patients. Strategies to improve outcomes should also include use of clear referral criteria, use of a multi-disciplinary approach, and patient education.
引用
收藏
页码:376 / 387
页数:12
相关论文
共 50 条
  • [11] Management of Diabetes in Patients with Chronic Kidney Disease
    Ahmed, Ziauddin
    Simon, Barbara
    Choudhury, Devasmita
    POSTGRADUATE MEDICINE, 2009, 121 (03) : 52 - 60
  • [12] Clinical assessment and treatment of diabetes in patients with chronic kidney disease
    Carretero Gomez, J.
    Arevalo Lorido, J. C.
    REVISTA CLINICA ESPANOLA, 2018, 218 (06): : 305 - 315
  • [13] Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: The ENTRED surveys (2001 and 2007)
    Assogba, G. F. A.
    Couchoud, C.
    Roudier, C.
    Pornet, C.
    Fosse, S.
    Romon, I.
    Druet, C.
    Stengel, B.
    Fagot-Campagna, A.
    DIABETES & METABOLISM, 2012, 38 (06) : 558 - 566
  • [14] Chronic kidney disease screening and renoprotection in type 2 diabetes
    Agaba, E. I.
    Puepet, F. H.
    Ugoya, S. O.
    Agaba, P. A.
    Adabe, R.
    Duguru, M.
    Rowland, A. I.
    ANNALS OF AFRICAN MEDICINE, 2009, 8 (01) : 52 - 54
  • [15] Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
    Mahaffey, Kenneth W.
    Tuttle, Katherine R.
    Arici, Mustafa
    Baeres, Florian M. M.
    Bakris, George
    Charytan, David M.
    Cherney, David Z., I
    Chernin, Gil
    Correa-Rotter, Ricardo
    Gumprecht, Janusz
    Idorn, Thomas
    Pugliese, Giuseppe
    Rasmussen, Ida Kirstine Bull
    Rasmussen, Soren
    Rossing, Peter
    Sokareva, Ekaterina
    Mann, Johannes F. E.
    Perkovic, Vlado
    Pratley, Richard
    EUROPEAN HEART JOURNAL, 2024, : 1096 - 1108
  • [16] Management of diabetes mellitus in patients with chronic kidney disease
    Allison J. Hahr
    Mark E. Molitch
    Clinical Diabetes and Endocrinology, 1 (1):
  • [17] Progress in the management of patients with diabetes and chronic kidney disease
    Garcia, Leonardo Pozo
    Thomas, Sandhya S.
    Rajesh, Harsith
    Navaneethan, Sankar D.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (05) : 456 - 463
  • [18] Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes
    Khan, Muhammad Shahzeb
    Lea, Janice P.
    BMC NEPHROLOGY, 2024, 25 (01)
  • [19] Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes
    Sridhar, Vikas S.
    Limonte, Christine P.
    Groop, Per-Henrik
    Heerspink, Hiddo J. L.
    Pratley, Richard E.
    Rossing, Peter
    Skyler, Jay S.
    Cherney, David Z. I.
    DIABETOLOGIA, 2024, 67 (01) : 3 - 18
  • [20] Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
    Filippatos, Gerasimos
    Anker, Stefan D.
    Agarwal, Rajiv
    Pitt, Bertram
    Ruilope, Luis M.
    Rossing, Peter
    Kolkhof, Peter
    Schloemer, Patrick
    Tornus, Ingo
    Joseph, Amer
    Bakris, George L.
    CIRCULATION, 2021, 143 (06) : 540 - 552